ReviewPharmaceuticals (Basel, Switzerland)2019
The Dark Side: Photosensitizer Prodrugs.
Review in Pharmaceuticals (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Doubly protected ester prodrug of 5-aminolevulinic acid for enhanced cell uptake and photoinactivation.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026Article
- Natural Product-Based Upconversion-Downshifting Photosensitizers in Photodynamic Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Doubly protected ester prodrug of 5-aminolevulinic acid for enhanced cell uptake and photoinactivation.Research square · 2026Article
- Cold atmospheric plasma-enabled platelet vesicle incorporated iron oxide nano-propellers for thrombolysis.Materials today. Bio · 2023Article
- An Efficient 5-Aminolevulinic Acid Photodynamic Therapy Treatment for Human Hepatocellular Carcinoma.International journal of molecular sciences · 2023Article
- Infections associated with SARS-CoV-2 exploited via nanoformulated photodynamic therapy.ADMET & DMPK · 2023Review
- Targeted Nanoparticle Photodynamic Diagnosis and Therapy of Colorectal Cancer.International journal of molecular sciences · 2021Article
- Photophysical Properties of Protoporphyrin IX, Pyropheophorbide-a and PhotofrinPharmaceuticals (Basel, Switzerland) · 2021Article
- Recent Advances in Photosensitizers as Multifunctional Theranostic Agents for Imaging-Guided Photodynamic Therapy of Cancer.Theranostics · 2021Review
- An Optimized Approach for Prostate Image Segmentation Using K-Means Clustering Algorithm with Elbow Method.Computational intelligence and neuroscience · 2021Article
- Singlet oxygen generation on a superhydrophobic surface: Effect of photosensitizer coating and incident wavelength onPhotochemistry and photobiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Photodynamic therapy (PDT) and photodiagnosis (PD) are essential approaches in the field of biophotonics. Ideally, both modalities require the selective sensitization of the targeted disease in order to avoid undesired phenomena such as the destruction of healthy tissue, skin photosensitization, or mistaken diagnosis. To a large extent, the occurrence of these incidents can be attributed to "background" accumulation in non-target tissue. Therefore, an ideal photoactive compound should be optically silent in the absence of disease, but bright in its presence. Such requirements can be fulfilled using innovative prodrug strategies targeting disease-associated alterations. Here we will summarize the elaboration, characterization, and evaluation of approaches using polymeric photosensitizer prodrugs, nanoparticles, micelles, and porphysomes. Finally, we will discuss the use of 5-aminolevulinc acid and its derivatives that are selectively transformed in neoplastic cells into photoactive protoporphyrin IX.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.